Teladoc Health, Inc. provides virtual healthcare services on a business-to-business basis in the United States and internationally. It covers various clinical conditions, including non-critical, episodic care, chronic, and complicated cases like cancer and congestive heart failure, as well as offers telehealth solutions, chronic condition management, expert medical services, behavioral health solutions, guidance and support, and platform and program services. It serves health employers, health plans, hospitals, health systems, and insurance and financial services companies. The company offers its products and services under the Teladoc, Livongo, Advance Medical, Best Doctors, BetterHelp, and HealthiestYou brands. The company was formerly known as Teladoc, Inc. and changed its name to Teladoc Health, Inc. in August 2018. Teladoc Health, Inc. was Incorporated in 2002 and is headquartered in Purchase, New York.
IPO Year: 2015
Exchange: NYSE
Website: teladochealth.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/15/2024 | $14.00 | Buy | Goldman |
| 9/17/2024 | $8.00 → $10.00 | Hold | Jefferies |
| 2/29/2024 | $22.00 | Overweight | Cantor Fitzgerald |
| 2/26/2024 | $17.00 | Market Perform | Leerink Partners |
| 1/17/2024 | $33.00 → $22.00 | Buy → Neutral | DA Davidson |
| 1/3/2024 | $26.00 | Overweight | Barclays |
| 4/12/2023 | $25.00 | Equal-Weight | Stephens |
| 2/23/2023 | $34.00 | Market Perform → Outperform | SVB Securities |
| 10/24/2022 | Sell → Neutral | Guggenheim | |
| 9/16/2022 | Sector Weight | KeyBanc Capital Markets |
4 - Teladoc Health, Inc. (0001477449) (Issuer)
4 - Teladoc Health, Inc. (0001477449) (Issuer)
4 - Teladoc Health, Inc. (0001477449) (Issuer)
4 - Teladoc Health, Inc. (0001477449) (Issuer)
4 - Teladoc Health, Inc. (0001477449) (Issuer)
4 - Teladoc Health, Inc. (0001477449) (Issuer)
4 - Teladoc Health, Inc. (0001477449) (Issuer)
4 - Teladoc Health, Inc. (0001477449) (Issuer)
4 - Teladoc Health, Inc. (0001477449) (Issuer)
4 - Teladoc Health, Inc. (0001477449) (Issuer)
PURCHASE, NY, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, today reported financial results for the full year ended December 31, 2024 ("Full Year 2024") and three months ended December 31, 2024 ("Fourth Quarter 2024"). Unless otherwise noted, percentage and other changes are relative to the full year ended December 31, 2023 ("Full Year 2023") and three months ended December 31, 2023 ("Fourth Quarter 2023"). Full Year and Fourth Quarter 2024 Highlights Full Year 2024 revenue of $2,569.6 million, down 1% year-over-year, and Fourth Quarter 2024 revenue of $640.5 million, down 3% year-over-yearFull Year 2024 net loss of
PURCHASE, NY, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Teladoc Health Inc. (NYSE:TDOC), the global leader in virtual care, announced that it will release fourth quarter 2024 results on Wednesday, February 26, 2025, after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. ET on the same day. Conference Call DetailsThe conference call can be accessed by dialing 1-833-470-1428 for U.S. participants and using the access code # 259200. For international participants, please visit the following link for global dial-in numbers: https://www.netroadshow.com/events/global-numbers?confId=72270. A live audio webcast will also be available online at http
PURCHASE, NY, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, today reported financial results for the three months ended September 30, 2024 ("Third Quarter 2024"). Unless otherwise noted, percentage and other changes are relative to the three months ended September 30, 2023 ("Third Quarter 2023"). Third Quarter 2024 Highlights Third Quarter 2024 revenue of $640.5 million, down 3% year-over-yearThird Quarter 2024 net loss of $33.3 million, or $0.19 per shareThird Quarter 2024 adjusted EBITDA of $83.3 million, down 6% year-over-yearIntegrated Care segment revenue of $383.7 million, up 2% year-over-year, and adjusted EBIT
PURCHASE, NY, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Teladoc Health Inc. (NYSE:TDOC), the global leader in whole-person virtual care, announced that it will release third quarter 2024 results on Wednesday, October 30, 2024, after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. E.T. on the same day. Conference Call DetailsThe conference call can be accessed by dialing 1-833-470-1428 for U.S. participants and using the access code # 781291. For international participants, please visit the following link for global dial-in numbers: https://www.netroadshow.com/events/global-numbers?confId=72270. A live audio webcast will also be available o
PURCHASE, NY, July 31, 2024 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, today reported financial results for the three months ended June 30, 2024 ("Second Quarter 2024"). Unless otherwise noted, percentage and other changes are relative to the three months ended June 30, 2023 ("Second Quarter 2023"). Financial and Operational Highlights for Second Quarter 2024 Second Quarter 2024 revenue of $642.4 million, down 2% year-over-yearSecond Quarter 2024 net loss of $837.7 million, or $4.92 per share, including a goodwill impairment charge of $790.0 million, or $4.64 per shareSecond Quarter 2024 adjusted EBITDA of $89.5 million, up 24%
PURCHASE, NY, July 17, 2024 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE:TDOC), the global leader in whole-person virtual care, announced that it will release second quarter 2024 results on Wednesday, July 31, 2024, after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. E.T. on the same day. Conference Call Details The conference call can be accessed by dialing 1-833-470-1428 for U.S. participants and using the access code # 453227. For international participants, please visit the following link for global dial-in numbers: https://www.netroadshow.com/conferencing/global-numbers?confId=68682. A live audio webcast will also be avai
PURCHASE, NY, April 25, 2024 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, today reported financial results for the three months ended March 31, 2024 ("First Quarter 2024"). Unless otherwise noted, percentage and other changes are relative to the three months ended March 31, 2023 ("First Quarter 2023"). Financial and Operational Highlights for First Quarter 2024 First Quarter 2024 revenue grows 3% year-over-year to $646.1 millionFirst Quarter 2024 net loss of $81.9 million, or $0.49 per shareFirst Quarter 2024 adjusted EBITDA of $63.1 million, up 20% year-over-year "We are pleased to report a solid start to the year, with strength
PURCHASE, NY, April 12, 2024 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE:TDOC), the global leader in whole-person virtual care, announced that it will release first quarter 2024 results on Thursday, April 25, 2024, after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. E.T. on the same day. Conference Call DetailsThe conference call can be accessed by dialing 1-833-470-1428 for U.S. participants and using the access code # 901506. For international participants, please visit the following link for global dial-in numbers: https://www.netroadshow.com/conferencing/global-numbers?confId=60046. A live audio webcast will also be availa
Fourth quarter 2023 revenue increase of 4% and full year 2023 revenue increase of 8% to $2,602.4 millionFourth quarter 2023 net loss of $28.9 million, or $0.17 per share, and full year 2023 net loss of $220.4 million, or $1.34 per shareFourth quarter 2023 adjusted EBITDA increase of 22% to $114.4 million and full year 2023 adjusted EBITDA increase of 33% to $328.1 million, resulting in the company's most profitable year-to-dateFull year 2023 operating cash flow of $350.0 million, up from $189.3 million; full year 2023 free cash flow of $193.7 million, up from $16.5 million; cash position of $1,123.7 million as of December 31, 2023Initiates 2024 guidance, provides three year outlook PURCHASE
PURCHASE, NY, Feb. 19, 2024 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE:TDOC), the global leader in whole-person virtual care, announced today that the conference call to review its fourth quarter 2023 results, previously scheduled for 4:30 p.m. E.T. on February 20, 2024, will now start at 5:00 p.m. E.T. on that same day. Conference Call DetailsThe conference call can be accessed by dialing 1-833-470-1428 for U.S. participants and using the access code # 825968. For international participants, please visit the following link for global dial-in numbers: https://www.netroadshow.com/conferencing/global-numbers?confId=60046. A live audio webcast will also be available online at https://ir.
The partnership enables Teladoc Health's employer clients and members more streamlined and fully integrated access to Carrum's value-based Centers of Excellence network for specialty care SAN FRANCISCO, March 13, 2025 /PRNewswire/ -- Carrum Health, the leader in value-based Centers of Excellence (COE) for specialty care, today announced a strategic partnership with Teladoc Health (NYSE:TDOC), the global leader in virtual care. The new arrangement will allow Teladoc Health's providers to seamlessly refer eligible members needing specialty care into Carrum's nationwide network of rigorously vetted, high quality providers. This means employers can contract directly through Teladoc Health's Conn
CHICAGO, March 12, 2025 (GLOBE NEWSWIRE) -- Cylinder, the leading virtual digestive health provider, today announced its partnership with Teladoc Health (NYSE:TDOC), the global leader in virtual care, to expand access to high-quality, personalized gastrointestinal care. Through this collaboration, Teladoc Health's health plan and employer customers can easily provide members access to Cylinder's evidence-based digestive health platform, through streamlined administrative services and integration enablement. Digestive health conditions affect up to 70 million Americans and drive significant healthcare costs — up to $136 billion annually. Cylinder's platform delivers precise diagnoses and p
PURCHASE, NY, March 11, 2025 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE:TDOC), the global leader in virtual care, today announced the expansion of its connected care partnerships across new care categories including digestive health, centers of excellence, fertility and family building. In addition, recently announced technology integrations will empower Teladoc Health's care providers and coaches to view members' eligibility for these services and seamlessly refer them to appropriate partner programs at the point of care. The latest enhancements are part of Teladoc Health's integrated care segment strategy to fuel use of its services and leverage the company's clinical strength and produ
PURCHASE, NY, March 06, 2025 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE:TDOC) today announced a pharmacy integration agreement with Eli Lilly's LillyDirect pharmacy partner, Gifthealth, which will help streamline access to FDA-approved Zepbound® (tirzepatide) for Teladoc Health members enrolled in its Comprehensive Weight Care Program. This option will help members without insurance coverage for GLP-1s for obesity have more seamless access to affordable, safe, and effective medicine. LillyDirect is Eli Lilly and Company's direct-to-consumer digital healthcare platform. Eligible Teladoc Health members, if prescribed Zepbound® by their Teladoc Health provider for an on-label indication, can h
PURCHASE, NY, March 05, 2025 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE:TDOC), the global leader in virtual care, today announced that it issued inducement awards to 21 new employees. Effective February 28, 2025 and March 1, 2025, in connection with the acquisition of Catapult Health on February 28, 2025, 19 employees of Catapult Health were granted awards of restricted stock units covering an aggregate of 365,282 shares of Teladoc Health's common stock, par value $0.001 per share ("Common Stock"), and awards of performance stock units covering a target of 324,270 shares of Common Stock. The restricted stock units vest, based on continued service to Teladoc Health, over two or three y
PURCHASE, NY, March 04, 2025 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE:TDOC), the global leader in virtual care, today announced new capabilities to its purpose-built, proprietary care delivery platform, called Prism, that will strengthen its ability to coordinate care with digital health partners and community care providers. New benefits to clinicians and patients include advanced referrals to Teladoc Health's digital and in-person care partners, while also increasing the value of each virtual care visit, using data insights to support clinicians in closing care gaps and improving population health for sponsoring employers and health plans. The announcement is part of Teladoc Health's
PURCHASE, NY, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, today reported financial results for the full year ended December 31, 2024 ("Full Year 2024") and three months ended December 31, 2024 ("Fourth Quarter 2024"). Unless otherwise noted, percentage and other changes are relative to the full year ended December 31, 2023 ("Full Year 2023") and three months ended December 31, 2023 ("Fourth Quarter 2023"). Full Year and Fourth Quarter 2024 Highlights Full Year 2024 revenue of $2,569.6 million, down 1% year-over-year, and Fourth Quarter 2024 revenue of $640.5 million, down 3% year-over-yearFull Year 2024 net loss of
PURCHASE, NY, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE:TDOC), the global leader in virtual care, announced today that Chuck Divita, chief executive officer, and Mala Murthy, chief financial officer, will participate in the TD Cowen 45th Annual Health Care Conference in Boston on Monday, March 3rd, 2025, at 10:30 a.m. ET. A live audio webcast and replay of the presentation will be available at http://ir.teladochealth.com/news-and-events/events-and-presentations. About Teladoc HealthTeladoc Health empowers all people everywhere to live their healthiest lives by transforming the healthcare experience. As the world leader in virtual care, Teladoc Health uses proprietar
PURCHASE, NY, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE:TDOC), the global leader in virtual care, today announced that it issued inducement awards to two new employees. Effective February 1, 2025, in connection with commencing employment, two new non-executive employees of Teladoc Health were granted awards of restricted stock units covering an aggregate of 35,000 shares of Teladoc Health's common stock, par value $0.001 per share. The restricted stock units vest, based on continued service to Teladoc Health, as to one-third of the underlying shares on the first anniversary of the grant date, with the remainder vesting quarterly over two years thereafter. The awards w
PURCHASE, NY, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE:TDOC), the global leader in virtual care, today announced that it has signed a definitive agreement to acquire Catapult Health, a leading provider of virtual preventive care services. The company plans to leverage Catapult Health's innovative approach to patient-centric at-home diagnostic testing, as well as its high-touch engagement and clinical support model, to complement Teladoc Health's industry-leading suite of integrated solutions. Building on its over 93-million-member base, Teladoc Health's acquisition of Catapult Health supports the company's integrated care segment strategy, discussed most recently during th
4 - Teladoc Health, Inc. (0001477449) (Issuer)
4 - Teladoc Health, Inc. (0001477449) (Issuer)
4 - Teladoc Health, Inc. (0001477449) (Issuer)
SC 13G - Teladoc Health, Inc. (0001477449) (Subject)
SC 13G/A - Teladoc Health, Inc. (0001477449) (Subject)
SC 13G/A - Teladoc Health, Inc. (0001477449) (Subject)
SC 13G/A - Teladoc Health, Inc. (0001477449) (Subject)
SC 13G/A - Teladoc Health, Inc. (0001477449) (Subject)
SC 13G/A - Teladoc Health, Inc. (0001477449) (Subject)
SC 13G/A - Teladoc Health, Inc. (0001477449) (Subject)
SC 13G/A - Teladoc Health, Inc. (0001477449) (Subject)
SC 13G/A - Teladoc Health, Inc. (0001477449) (Subject)
SC 13G/A - Teladoc Health, Inc. (0001477449) (Subject)
144 - Teladoc Health, Inc. (0001477449) (Subject)
144 - Teladoc Health, Inc. (0001477449) (Subject)
S-8 - Teladoc Health, Inc. (0001477449) (Filer)
10-K - Teladoc Health, Inc. (0001477449) (Filer)
8-K - Teladoc Health, Inc. (0001477449) (Filer)
144 - Teladoc Health, Inc. (0001477449) (Subject)
10-Q - Teladoc Health, Inc. (0001477449) (Filer)
8-K - Teladoc Health, Inc. (0001477449) (Filer)
144 - Teladoc Health, Inc. (0001477449) (Subject)
8-K - Teladoc Health, Inc. (0001477449) (Filer)
Jason Gorevic to depart the company, effective immediatelyCFO Mala Murthy appointed acting chief executiveTeladoc Health reaffirms guidance PURCHASE, NY, April 05, 2024 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE:TDOC), the global leader in whole-person virtual care, today announced that Jason Gorevic is departing the company, effective immediately. The Board of Directors has appointed Mala Murthy acting Chief Executive Officer while it searches for Mr. Gorevic's permanent successor. Ms. Murthy is a seasoned industry leader who has served as the Company's Chief Financial Officer since 2019, and she will continue serving in this role during this transition period. The Board has ret
PURCHASE, NY, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE:TDOC), the global leader in whole-person virtual care, today appointed Eric Evans to the company's board of directors. Mr. Evans, currently chief executive officer and director of Brentwood, TN-based Surgery Partners, Inc. (NASDAQ:SGRY), is a recognized healthcare and hospital executive with significant experience leading complex organizations operating at the intersection of care and technology. Mr. Evans joins the board following the retirement of Senator William Frist, M.D. earlier this year, and will serve on the board's compensation committee. David B. Snow, Jr., non-executive Chairman of the company's board,
After spending two decades successfully scaling multiple healthcare technology companies, Perez joins Big Health to accelerate the commercial coverage and reimbursement for digital therapeutics Big Health, a digital therapeutics company dedicated to helping millions back to good mental health, today announced the appointment of Gabriela Perez as Chief Commercial Officer. In her new role, Perez will oversee Big Health's global commercial growth and strategy, including sales, client management, strategic partnerships, and new markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220203005297/en/Big Health Chief Commercial Office
BRISBANE, Calif., April 14, 2021 /PRNewswire/ -- Caption Health, a leading medical artificial intelligence (AI) company driving better health outcomes by increasing access to ultrasound, announced today that it has appointed Steve Cashman as its new President and Chief Executive Officer, effective immediately. Cashman joins Caption Health after serving as Chief Commercial Officer at InTouch Health, which was acquired by Teladoc (NYSE:TDOC) in 2020. At InTouch, Cashman oversaw the company's domestic and global sales, as well as product, marketing, customer service and clinical
Goldman initiated coverage of Teladoc with a rating of Buy and set a new price target of $14.00
Jefferies reiterated coverage of Teladoc with a rating of Hold and set a new price target of $10.00 from $8.00 previously
Cantor Fitzgerald initiated coverage of Teladoc with a rating of Overweight and set a new price target of $22.00
Leerink Partners initiated coverage of Teladoc with a rating of Market Perform and set a new price target of $17.00
DA Davidson downgraded Teladoc from Buy to Neutral and set a new price target of $22.00 from $33.00 previously
Barclays initiated coverage of Teladoc with a rating of Overweight and set a new price target of $26.00
Stephens initiated coverage of Teladoc with a rating of Equal-Weight and set a new price target of $25.00
SVB Securities upgraded Teladoc from Market Perform to Outperform and set a new price target of $34.00
Guggenheim upgraded Teladoc from Sell to Neutral
KeyBanc Capital Markets initiated coverage of Teladoc with a rating of Sector Weight